★ The views expressed in this document reflect the opinion of the individuals and not necessarily those of the institutions that they represent. Placenta accreta is a histopathologic term for a condition first described in 1937 by obstetrician Frederick C. Irving and pathologist Arthur T.
Hertig at the Boston Lying-In Hospital.
1 Their study described 18 new cases of placenta accreta presenting with "the abnormal adherence of the afterbirth in whole or in parts to the underlying uterine wall."
Attempts to remove the placenta led to major postpartum hemorrhage that required emergency or secondary hysterectomy to control the bleeding in 14 cases. The histologic criterion used for their diagnosis of accreta placentation was the complete or partial absence of the decidua basalis-a sign that is still used today in many clinical and histopathological studies. 2 There were case reports published in the decade before Irving and Hertig published their series but the detailed description of the cases included in their study makes it the first pivotal publication on placenta accreta.
Irving and Hertig described all their cases as "vera" or "adherent,"
where the villi were attached to the surface of the myometrium without invading it. They discussed the possibility of deeper penetration of the villi into the myometrium, but none of their cases or those described in their literature review presented with histologic features of myometrial invasion by placental tissue. Only one of their cases and another from their literature review had undergone a prior cesarean delivery. More than 95% of the cases reported in their paper had a history of manual removal, curettage, and/or endometritis. Thirty years later, similar reviews of the literature reported a history of one or more cesarean deliveries in more than a quarter of women presenting with placenta accreta, as well as the occurrence of the more invasive forms. 3, 4 Over the last 40 years, cesarean delivery rates around the world have risen from less than 10% to over 30%, and almost simultaneously a 10-fold increase in the incidence of placenta accreta spectrum (PAS) disorders has been reported in most medium-and high-income countries. 5 It should be noted that changes in the incidence of PAS disorders secondary to increased cesarean delivery rates may be delayed by up to 10 years, depending on birth rates and interpregnancy intervals, which vary in different parts of world. For the USA alone, it was estimated in 2011 that, if the cesarean delivery rate continues to increase as it has done before, by 2020 the cesarean delivery rate will be over 50% and there will be an additional 4504 annual cases of PAS disorders and 130 maternal deaths due to its complications. 6 Thus, it is not surprising that 80 years later, more than 90% of women presenting with a placenta accreta have had at least one prior cesarean delivery. [5] [6] [7] [8] [9] PAS disorders were first defined by Luke et al. 3 to include both abnormally adherent and invasive placentas. Three categories are now considered: (1) adherent placenta accreta, also described by pathologists as "placenta creta, vera or adherenta" when the villi simply adhere to the myometrium; (2) placenta increta, when the villi invade the myometrium; and (3) placenta percreta, when villi invade the full thickness of the myometrium including the uterine serosa and sometimes adjacent pelvic organs. [3] [4] [5] Variations in the lateral extension of myometrial invasion also divide PAS disorders into the focal, partial, or total categories, depending on the number of placental cotyledons involved. Finally, the degree of villous adhesion or invasion is rarely uniform throughout the placenta, limiting the accuracy of microscopic diagnosis when the whole uteroplacental interface is not available for analysis. 3 This terminology describes accurately the spectrum of accreta placentation; however, an increasing number of clinicians have started using an archaic "Victorian" etymology, i.e. "morbidly adherent placenta" (MAP), to describe the different grades of accreta placentation. This is confusing and misleading, as technically it excludes the invasive forms of PAS disorders. Other terms used include "placental adhesive disorders," "abnormally adherent placenta," "abnormal pla- 14 Ultrasound imaging is the most commonly used technique to diagnose PAS disorders prenatally.
However, the terminology employed to describe the different categories of ultrasound signs was also heterogeneous and complex.
Together with the lack of detailed histopathologic correlations in most studies, this may explain why no single ultrasound sign or set combination of ultrasound signs has been found to be specific for the depth of abnormal placentation, and accurate for the differential diagnosis between adherent and invasive placentation. [15] [16] [17] The
European Working Group on Abnormally Invasive Placenta (EW-AIP) and the AIP international expert group have recently proposed a standardized description of ultrasound signs used in the diagnosis of PAS disorders. 18, 19 Ultrasound signs of adherent and invasive placentation vary with gestational age and depend on the thickness and composition of the placental bed, number of prior uterine scars, presence of scar defects between pregnancies, depth of invasion, and the lateral extension of the villous tissue. 17 Prospective studies providing correlation between prenatal imaging findings, clinical data at delivery, and histopathology are essential to improve the screening, diagnosis, and management of PAS disorders. Research protocols should be standardized and used by both clinicians and pathologists to better define the ultrasound signs that may be useful in the screening of women at high risk for PAS disorders.
There is also wide variation globally on the management of PAS disorders, with some centers opting for a radical approach, whereas others have proposed a range of conservative approaches. 20, 21 Over the last decade, there has been an increasing number of case reports, cohort studies, modeling work, and systematic reviews on the diag- After the three-round process was complete, the members of the panel were asked to read the final version and provide written consent for their name to be included in the panel list for that chapter. The consensus process for the four chapters was concluded in July 2017.
The aim of these consensus guidelines is to improve the diagnosis and management of PAS disorders throughout the world, thus reducing the burden of maternal mortality and long-term sequelae that arise from this disease.
